Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-17	$0.000000	-	5

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 12:25:32 2026-06-01 pm EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.5K 81.67K 75.28K 142K 9.75M 145K 976K 384K 4.78M 380K 372K 16.44M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.9M 9.14M 8.42M 15.88M 1.09B 16.23M 109M 42.97M 535M 42.56M 41.63M 1.84B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEEL.Q

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/29/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
1/12/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%
1/12/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	-	-100.00%	136
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+42.72%	+73.32%	52.1B
ARGENX SE	+0.24%	-1.54%	+52.85%	+71.85%	53.83B
INSMED INCORPORATED	+0.80%	-6.31%	+5.62%	+417.78%	23.48B
BIONTECH SE	-0.09%	-0.01%	-16.85%	-15.41%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+29.53%	-9.47%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.67%	-30.65%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+314.96%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+25.17%	+644.30%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+25.75%	+189.74%	14.06B
Average	+987.50%	-2.36%	+40.54%	+155.64%	23.36B
Weighted average by Cap.	-2.80%	-2.36%	+39.55%	+143.13%

	2022	2023
Net sales	-	2.2 1.93 1.78 1.64 3.09 212.15 3.15 21.23 8.35 103.9 8.27 8.09 357.69
Net income	-73.53M -64.26M -59.3M -54.66M -103M -7.08B -105M -709M -279M -3.47B -276M -270M -11.94B	-37.88M -33.11M -30.55M -28.16M -53.07M -3.65B -54.25M -365M -144M -1.79B -142M -139M -6.15B
Net Debt	4.59M 4.01M 3.7M 3.41M 6.43M 442M 6.57M 44.23M 17.4M 216M 17.23M 16.86M 745M	11.23M 9.82M 9.06M 8.35M 15.74M 1.08B 16.09M 108M 42.58M 530M 42.18M 41.26M 1.82B